Effect of Vigabatrin in Refractory Autoimmune Encephalitis Patients

• Status: Withdrawn
• Trial end date: 2020-09-09
• Target enrollment: 0
• Participant gender: All

Summary

Investigation of efficacy of vigabatrin in refractory autoimmune encephalitis patients

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Seoul National University Hospital
• Treatments: Vigabatrin

Criteria

Inclusion Criteria:

• Age 18-85

• Possible autoimmune encephalitis

• Patients who have been diagnosed and treated for encephalitis for more than 4 weeks

• Patients with epilepsy (EEG finding or clinically)

Exclusion Criteria:

• septic shock, fever >38.5 ℃, O2 saturation <90%, respiratory rate >25, HR >120

• previously, mRS=3 or mRS>3

• MMSE<20

• Patients who have terminal disease

• eye problem

• pregnancy